


🏠 [Home page](#) > [NEWS](#) > [Company News](#) > FDA Greenlights PrimeLink Bio’s Clinical Trial of PLB-002

## FDA Greenlights PrimeLink Bio’s Clinical Trial of PLB-002

Published on. 2025-10-09 15:18

Recently, PrimeLink Bio, an innovative biopharma focused on the development of next-generation antibody-drug conjugates (ADCs), announced that its first pipeline candidate, PLB-002 (an anti-Claudin6 ADC), has received Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA).



PrimeLink Bio will initiate a multi-center, open-label, dose escalation and expansion clinical trial to evaluate the safety and efficacy of PLB-002 in adults with advanced solid tumors.

Dr. Yin, Founder of PrimeLink Bio, remarked: “FDA IND clearance for PLB-002 is a major milestone for the company. PLB-002 is an anti-CLDN6 ADC generated on our flexible, modular ADC technology platform and has the potential to be best-in-class. It has demonstrated remarkable efficacy in preclinical models and could become a new option for cancer patients. As our first program to reach the clinic, PLB-002 also marks the start of our clinical journey. We will continue advancing additional pipeline candidates into human studies.”

### About PLB-002

PLB-002 is an anti-Claudin 6 ADC, a tight junction protein specifically expressed in solid tumors—most notably ovarian, non-small-cell lung, endometrial and testicular cancers—while barely expressed in healthy adult tissues. Discovered and advanced using PrimeLink Bio’s proprietary technology platform, PLB-002 has a much broader therapeutic window and great PK profile. Pre-clinical data has shown that PLB-002 is highly promising for the treatment of ovarian cancer, non-small cell lung cancer (NSCLC) and other CLDN6-positive solid tumors.

### About PrimeLink Bio

Founded in July 2021, PrimeLink Bio is an innovative biopharmaceutical company dedicated to the development of next-generation antibody–drug conjugates (ADCs). Guided by the principle of “tailoring optimal ADC structures for specific targets,” the company has developed a flexible, modular platform with high hydrophilicity, compatibility, and flexibility that enables novel strategies to overcome the safety liabilities and resistance mechanisms limiting current ADC therapies. PrimeLink Bio has built the pipeline spanning single-target ADCs and novel modalities such as bispecific ADCs and dual-payload ADCs. Three programs have already reached the PCC stage. Backed by its innovative technology platform and differentiated product pipelines, PrimeLink Bio has raised a total of RMB 150





[About Us](#)

[Technology](#)

[Pipeline](#)

[Team](#)

[News](#)

[Contact Us](#)



Pre: [None](#)

[Dual-Payload ADCs: A New Chapter in Cancer Therapy](#) Next:

Pre: [None](#)



Next: [Dual-Payload ADCs: A New Chapter in Cancer Therapy](#)

[About Us](#)

[Technology](#)

[Pipeline](#)

[Team](#)

[News](#)

[Contact Us](#)

Tel:  
0086 512-62652000

E-mail:  
hr@primelinkbio.com

Add:  
Building 4, Suhua Science  
Park , No.208 Tongyuan  
Road, Suzhou Industrial  
Park

Follow Us

©2022 PrimeLink BioTherapeutics Powered by: CEglobal

苏ICP备  
2021049115  
号-1



online consultation

Please enter the required content



send

